Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103207 · ClinicalTrials.gov registry record · Phase 2
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00103207 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 72 participants.
The verdict
NCT00103207, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well cetuximab works in treating patients with recurrent or stage IIIB or stage IV lung cancer.
Interventions
- BIOLOGICAL cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2005-10-13 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103207
The ClinicalTrials.gov registry entry for NCT00103207 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cetuximab is the first listed.
NCT00103207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103207 about?
NCT00103207 is a clinical study titled "Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer". RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well cetuximab ...
What is the current status of trial NCT00103207?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2005-10-13. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00103207?
The interventions under investigation include: cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00103207?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.